ReviewCJC open2025
Health Resource Utilization and Outcomes Among Patients Who Receive Extracorporeal Membrane Oxygenation.
Review in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinician Perspectives on the Extracorporeal Membrane Oxygenation Decision-Making Process.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is a high-cost, resource-intensive intervention for severe cardiac and respiratory failure. Survivors of ECMO have healthcare needs that extend beyond their acute hospitalization, placing significant demands on healthcare systems and society. As ECMO use increases globally, understanding the healthcare and economic burden of ECMO survivorship is needed to improve long-term outcomes of ECMO survivors and optimize resource allocation within healthcare systems. Methods: We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Emcare, Scopus, and Web of Science from inception to October 1, 2024. We included studies published in English that reported post-discharge healthcare resource utilization and costs for adult survivors of ECMO. Results: From 1889 articles screened, 24 studies met our inclusion criteria. Most were retrospective cohort studies conducted in North America between 2010 and 2024. Sample sizes ranged from 12 to 23,876 patients, with in-hospital mortality rates between 28.5% and 67.4%. Thirty-day readmission rates ranged from 10.0% to 43.8%, with 90-day rates ranging from 21.1% to 53.0%. One study reported a mean 30-day readmission cost of $62,150 (in 2023 US dollars). Only 5 studies (20.8%) reported total healthcare costs up to 6 months and 1 year. Conclusions: ECMO survivorship is gaining increased attention in research and clinical practice, yet significant gaps remain in our understanding of long-term healthcare resource utilization and costs. Our review reveals very limited information, indicating an urgent need for more comprehensive and granular data to guide clinical and policy decisions and achieve healthcare system efficiency.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.